S
RLAY icon

SignatureFD’s Relay Therapeutics RLAY Stock Holding History

SignatureFD’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.9K Sell
2,668
-456
-15% -$6.62K ﹤0.01% 1890
2026
Q1 		$31.1K Hold
3,124
– – ﹤0.01% 1990
2025
Q4 		$26.4K Hold
3,124
– – ﹤0.01% 1983
2025
Q3 		$16.3K Hold
3,124
– – ﹤0.01% 2206
2025
Q2 		$10.8K Buy
3,124
+1,996
+177% +$5.94K ﹤0.01% 2322
2025
Q1 		$2.96K Buy
1,128
+968
+605% +$3.79K ﹤0.01% 2768
2024
Q4 		$659 Buy
+160
New +$871 ﹤0.01% 3104
2024
Q3 		– Sell
-624
Closed -$4.07K – 3303
2024
Q2 		$4.07K Buy
+624
New +$4.26K ﹤0.01% 2578
2023
Q3 		– Sell
-75
Closed -$942 – 3287
2023
Q2 		$942 Sell
75
-463
-86% -$5.76K ﹤0.01% 2985
2023
Q1 		$8.86K Buy
+538
New +$9.65K ﹤0.01% 2271
2022
Q2 		– Sell
-51
Closed -$2K – 3307
2022
Q1 		$2K Buy
+51
New +$1.24K ﹤0.01% 2844
2021
Q4 		– Sell
-495
Closed -$16K – 3242
2021
Q3 		$16K Buy
+495
New +$16.7K ﹤0.01% 1863

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

SignatureFD's RLAY Position: Q2 2026 in Review

SignatureFD reduced its Relay Therapeutics (RLAY) stake by 15% in Q2 2026, selling an estimated $6.62K and leaving 2,668 shares worth $49.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1890.

SignatureFD first reported a position in RLAY in Q3 2021 and has held it in 12 quarters since. 259 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • SignatureFD held 2,668 shares of Relay Therapeutics worth $49.9K as of Q2 2026.
  • SignatureFD sold 456 Relay Therapeutics shares in Q2 2026, an estimated $6.62K.
  • Relay Therapeutics made up ﹤0.01% of SignatureFD's portfolio in Q2 2026, its #1890 holding.
  • SignatureFD first reported a position in Relay Therapeutics in Q3 2021 and has held it in 12 quarters since.
  • 259 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.